Peter Flynn, PhD President & CEO, Arialys Therapeutics Dr. Flynn has more than 20 years of executive leadership experience in the biotech industry, scaling companies through key financings, IPOs and pharma partnerships and advancing novel therapeutics from scientific breakthrough to the clinic, and commercializing FDA-approved medicines. Prior to joining Arialys, Dr. Flynn was Cofounder and Chief Operating Officer of Artiva Biotherapeutics, where he oversaw business development and strategy, research, manufacturing, and corporate operations. During his time at Artiva, the company achieved significant financing, clearance of several INDs and corporate partnerships with Merck and Affimed. Prior to Artiva, Dr. Flynn was the Global Head of Development and a senior executive at Orexigen, where he oversaw the post-marketing development and regulatory aspects of Contrave™, an FDA-approved weight-loss prescription medication. Prior to Orexigen, Dr. Flynn was Senior Vice President, Early Program Development at Fate Therapeutics where he was a member of the senior executive team for Fate’s IPO in 2013. Prior to Fate, he was Vice President of Research at Ren Pharmaceuticals. Dr. Flynn started his industry career at the antibody therapeutics company KaloBios. Dr. Flynn received a Ph.D. in biochemistry from ICRF / UCL and was a postdoctoral fellow at the UCSF.